CLINICAL TRIALS PROFILE FOR MOUNJARO

All Clinical Trials for MOUNJARO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05708859 ↗	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	Not yet recruiting	Eli Lilly and Company	Phase 4	2023-02-01	A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
NCT05708859 ↗	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	Not yet recruiting	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Phase 4	2023-02-01	A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
NCT06073184 ↗	Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium	Not yet recruiting	University Health Network, Toronto	Phase 2	2024-09-01	The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes.
NCT06162715 ↗	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial	Not yet recruiting	Vanderbilt University Medical Center	Phase 2	2024-10-01	The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo.
NCT06734273 ↗	Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss	RECRUITING	Nicholas Skertich	EARLY_PHASE1	2025-03-10	This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.
NCT07179120 ↗	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	NOT_YET_RECRUITING	First Affiliated Hospital of Wenzhou Medical University	PHASE2	2026-05-01	Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving. What will happen in this study? This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups: Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts. Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated. Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated. All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up. Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join. How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates. What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

Clinical Trial Conditions for MOUNJARO

Condition Name

Condition Name for MOUNJARO
Intervention	Trials
Atypical Hyperplasia	1
Endometrial Cancer	1
Obesity & Overweight	1
Obesity and Obesity-related Medical Conditions	1

Condition MeSH

Condition MeSH for MOUNJARO
Intervention	Trials
Obesity	3
Hyperplasia	1
Behavior, Addictive	1
Endometrial Neoplasms	1

Clinical Trial Locations for MOUNJARO

Trials by Country

Trials by Country for MOUNJARO
Location	Trials
United States	4

Trials by US State

Trials by US State for MOUNJARO
Location	Trials
Maryland	1
Illinois	1
Tennessee	1
California	1

Clinical Trial Progress for MOUNJARO

Clinical Trial Phase

Clinical Trial Phase for MOUNJARO
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	2
Phase 4	1

Clinical Trial Status

Clinical Trial Status for MOUNJARO
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	3
Not yet recruiting	3
RECRUITING	1

Clinical Trial Sponsors for MOUNJARO

Sponsor Name

Sponsor Name for MOUNJARO
Sponsor	Trials
University Health Network, Toronto	1
Vanderbilt University Medical Center	1
Nicholas Skertich	1

Sponsor Type

Sponsor Type for MOUNJARO
Sponsor	Trials
Other	7
Industry	1

Last updated: May 20, 2026

Mounjaro (tirzepatide) clinical trials update, market analysis, and 2026–2030 projection

Mounjaro (tirzepatide) is scaling from early-type GLP-1/GIP blockbuster adoption into a category leader in type 2 diabetes and an expanding competitive set in obesity pharmacotherapy. The commercial trajectory is being shaped by (1) ongoing late-stage registrational work across additional metabolic and obesity indications, (2) manufacturing ramp constraints typical for incretin therapies, and (3) payer tightening, dose and access rules, and side-effect burden driving demand elasticity.

What clinical trials are running for Mounjaro (tirzepatide) right now?

Mounjaro’s trial program is anchored in type 2 diabetes outcomes and obesity/weight-loss outcomes, with additional efforts to define place in therapy relative to GLP-1-only drugs and to expand label coverage.

Key registrational trials in type 2 diabetes

SURPASS-series outcomes established tirzepatide’s efficacy across comparator classes and dosing schedules, producing the basis for multiple dose strengths and insurer uptake. The remaining clinical value is consolidation: durability, cardiovascular signal interpretation, and translation into broader patient segments.

Cardiovascular outcomes

• Trials completed in the SURPASS program support the company’s cardiovascular positioning, and subsequent readouts are being used by payers to refine risk-based coverage.

Key registrational trials in obesity and weight management

SURMOUNT-series studies drive the obesity indication expansion logic, with endpoints focused on weight loss magnitude, maintenance, and metabolic improvements. The commercial relevance is direct: obesity demand is broader than diabetes demand and has different payer gates.

What endpoints are most likely to influence next-step approvals?

Across tirzepatide’s remaining registrational lanes, the highest commercial sensitivity endpoints are:

• Durable weight loss maintenance beyond initial induction
• Cardiometabolic biomarkers tied to payer health outcomes
• Safety and tolerability in broader populations (GI intolerance mitigation, discontinuation rates)
• Real-world adherence patterns by dose and patient characteristics

How does Mounjaro’s efficacy compare with Ozempic, Wegovy, and Zepbound?

Tirzepatide vs GLP-1-only comparators

• The market differentiator is efficacy depth relative to GLP-1 monotherapies, which translates into a stronger “clinical value per prescription” story for payers when adherence is maintained.
• In practice, the competitive outcome is not only weight-loss percentage but also discontinuation risk and dose escalation pace.

Against other dual agonists

• Tirzepatide is also compared against competitors with overlapping mechanisms targeting GLP-1 or dual pathways. The competitive edge remains clinical depth, supported by trial endpoints and label breadth in diabetes and weight management.

Dosage and titration matter for demand

Commercial adoption depends on how quickly patients can reach higher doses without prohibitive GI adverse events. Payer policies frequently require step edits, documentation, or prior authorization. Real-world demand is therefore sensitive to:

• Titration duration tolerability
• Supply stability at higher doses
• Dose-response consistency across patient subgroups

When does Mounjaro lose exclusivity in the US and key international markets?

A full exclusivity and patent-expiration timetable requires jurisdiction-specific Orange Book listings and national patent family status. Without those listings in the request, a complete, accurate exclusivity calendar cannot be produced.

What is the Orange Book status of Mounjaro for generic entry risk?

A complete Orange Book status for tirzepatide requires the specific FDA product codes, application numbers, and patent lists currently published for each finished-dose strength and packaging configuration. Without those data, generic entry risk cannot be mapped accurately.

Which patents protect Mounjaro formulations and methods of use?

Patent coverage for tirzepatide typically spans:

• Composition and active ingredient claims
• Formulation claims for the drug product (stabilizers, buffers, concentration ranges, injection-device compatibility)
• Method-of-use claims for diabetes and weight management indications
• Process/manufacturing and stability-related claims

A complete count of patents, claim scope, assignees, and expiration dates requires current patent bibliographic data and Orange Book/INPADOC retrieval tied to the specific NDA and manufacturing site permissions. Without that dataset, the estate cannot be enumerated reliably.

Are there any Paragraph IV challenges to Mounjaro or litigation settlements that change the launch calendar?

Paragraph IV filings and litigation timelines are determinative for generic timing. Producing a litigation and settlement map requires docket-level retrieval for tirzepatide AND the specific FDA application numbers involved. Without that, no accurate legal timeline can be provided.

What biosimilar risks exist for tirzepatide (Mounjaro)?

Tirzepatide is a small molecule peptide-like drug, not a biologic product in the US BLA pathway. Biosimilar frameworks are not the relevant competitive threat. The primary generic threat is via ANDA-related routes or other small-molecule generic pathways, controlled by patent and regulatory exclusivity listed in FDA systems. A risk assessment requires up-to-date patent and exclusivity listings.

What manufacturing and supply constraints affect Mounjaro availability and sales?

For high-demand incretin therapies, the commercial ceiling is often set by:

• Drug substance and drug product capacity
• Fill-finish line constraints for specific pen formats
• Stability and cold-chain logistics for consistent distribution
• Demand allocation decisions by dose strength

Demand elasticity is frequently constrained by supply first, then by payer restrictions. In the US, supply ramp patterns for the highest dose strengths often determine whether incremental new prescriptions convert into filled scripts.

Market analysis: what is driving Mounjaro demand growth?

Category pull

• Type 2 diabetes population is large and expanding through diagnosis rates and comorbid cardiometabolic conditions.
• Obesity pharmacotherapy creates an additional, faster-growing payer and employer segment with different coverage rules than diabetes.

Clinical conversion

• Strong efficacy supports switching from GLP-1-only drugs and from non-incretin therapies.
• Dose titration tolerance drives conversion success. Patients who remain on therapy convert into longer-duration demand.

Payer dynamics

Payer strategies affecting commercial uptake:

• Prior authorization and step therapy against GLP-1 comparators
• Formulary placement by health plan segment
• Quantity limits or restrictions on dose increases
• Real-world outcomes requirements after a defined treatment period

Market size and revenue projection for Mounjaro 2026–2030

A credible projection requires baseline revenue, unit share, and channel distribution, plus a competition and access model. The current request does not include those numeric baselines, so only a directional, non-quantified framework can be stated.

Projection drivers

• Indication expansion pace: label breadth increases eligible patient pools.
• Dose mix and persistence: higher dose fill proportion and long-term continuation rates improve net revenue.
• Competition intensity: GLP-1-only and dual agonist rivals pressure price and formulary positioning.
• Access tightening: payers increasingly manage start/continue rules.

Projection scenarios (directional)

• Base case: continued share gains in diabetes and obesity with moderate payer friction and supply normalization.
• Upside case: faster persistence gains and broader coverage reduce drop-off, enabling deeper penetration in commercially insured and Medicare managed-care segments.
• Downside case: payer coverage becomes more restrictive and competitor pricing increases, leading to slower incremental uptake and higher discontinuation.

How does Mounjaro compare with competitors in pricing, formulary access, and uptake?

At a high level, the competitive set includes:

• GLP-1 monotherapies used for diabetes and obesity (often first-line in plan designs)
• Other dual agonists targeting overlapping weight-loss and cardiometabolic endpoints
• Biosimilar and generic substitutes are not a near-term direct substitution threat for branded tirzepatide

Market share dynamics typically hinge on:

• Formulary placement and step-edit flexibility
• Net price after rebates
• Clinical outcomes evidence package and payer health economics framing
• Patient experience and discontinuation rates

What risks could slow Mounjaro growth?

Key risk categories affecting near- to mid-term revenue:

• Tolerability-driven discontinuation: GI adverse events can raise attrition and reduce dose escalation completion.
• Payer tightening: more restrictive criteria or limited coverage windows.
• Supply normalization and utilization shifts: demand can shift to competitors if higher-dose availability lags.
• Safety signal interpretation: any emerging long-tail safety concerns can change plan coverage behavior.

What commercial opportunities exist for Mounjaro beyond current labels?

High-value opportunities typically include:

• Additional metabolic and cardiometabolic endpoints where tirzepatide’s trial results support label expansion.
• Earlier-line use where payer systems accept stronger weight and glycemic outcomes.
• New patient segmentation based on comorbidity profiles.

Key Takeaways

• Mounjaro’s clinical program is focused on consolidating outcomes and expanding obesity and broader metabolic coverage through SURPASS and SURMOUNT evidence.
• Competitive advantage is strongest where efficacy depth drives adherence and payer willingness to cover.
• Growth is most sensitive to persistence, payer access rules, and supply stability across higher-dose strengths.
• A precise 2026–2030 numeric revenue forecast and exclusivity calendar cannot be completed from the provided request without FDA patent listing and baseline financial inputs.

FAQs

1. Does Mounjaro have ongoing phase 3 trials for cardiovascular outcomes in type 2 diabetes?
2. How do SURMOUNT trial endpoints map to obesity payer coverage decisions for tirzepatide?
3. What is the typical titration schedule for Mounjaro and how does it affect persistence?
4. What are the main payer barriers to starting tirzepatide for weight management?
5. What differentiates Mounjaro’s competitive position versus GLP-1-only drugs in managed care formularies?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. ClinicalTrials.gov. (n.d.). Search results for tirzepatide (Mounjaro). U.S. National Library of Medicine.
3. SURPASS and SURMOUNT trial publications in peer-reviewed literature (n.d.).